HC Wainwright Has Pessimistic Outlook of STOK Q2 Earnings
Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) – Research analysts at HC Wainwright reduced their Q2 2025 earnings per share (EPS) estimates for Stoke Therapeutics in a report issued on Wednesday, May 14th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($0.68) for the quarter, down from […]
Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) – Research analysts at HC Wainwright reduced their Q2 2025 earnings per share (EPS) estimates for Stoke Therapeutics in a report issued on Wednesday, May 14th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($0.68) for the quarter, down from […]
